Cancercompass News: breast cancerCancerCompass is an online community committed to offering people living with cancer a place to receive cancer information and news, share knowledge, and share cancer treatment experiences. To learn more, visit our site today.Iressa Shows Promise For Treatment Of Metastatic Breast Cancer When Combined With Hormonal Therapy- May 30, 2008 Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center. These findings are surprising and represent the first positive study for Iressa in breast cancer, as well as for the entire class of drugs known as...http://www.cancercompass.com/cancer-news/1,14246,00.htm?rss=y Study Says New Radiation Therapy Technology For Breast Cancer Helps Protect Tissue, Adds Options For Patients- May 30, 2008 New research conducted at Moores Cancer Center at University of California, San Diego shows that the SAVI(TM) breast brachytherapy applicator, a new approach for delivering accelerated partial breast irradiation (APBI), may provide better protection of healthy tissue than other partial breast irradiation methods. The research team, led by Catheryn Yashar, M.D., assistant professor and chief of breast and gynecological services in the UC San Diego Department of Radiation Oncology, presented...http://www.cancercompass.com/cancer-news/1,14247,00.htm?rss=y Breast-specific Gamma Imaging Found To Be Highly Sensitive For Early Stage Breast Cancer- May 30, 2008 NEWPORT NEWS, Va. -- According to an article in the June issue of Radiology, researchers at The George Washington University Medical Center in Washington, D.C. have shown that Breast-Specific Gamma Imaging (BSGI) is highly sensitive in detecting the presence of cancer. The researchers determined that BSGI was a useful detection tool and that it was as sensitive as MRI for most cancers and perhaps more sensitive for ductal carcinoma in-situ, an early stage of breast cancer. BSGI, molecular...http://www.cancercompass.com/cancer-news/1,14248,00.htm?rss=y Study Suggests Chemotherapy Diminishes Fertility In Breast Cancer Patients- May 30, 2008 CHICAGO -- Pre-menopausal breast cancer survivors who were treated with chemotherapy following surgery were more likely to have diminished ovarian reserve - the capacity of the ovaries to provide eggs capable of being fertilized - compared to women who have never had breast cancer, according to a study led by Dana-Farber Cancer Institute investigators. Their findings will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), May 30-June 3, in Chicago. The...http://www.cancercompass.com/cancer-news/1,14244,00.htm?rss=y Affymetrix Technology Powers First Genomic Tumor Grading Test For Breast Cancer- May 30, 2008 SANTA CLARA, Calif. -- Affymetrix Inc. today announced that its technology powers the Ipsogen MapQuant Dx(TM) Genomic Grade, the first genomic test designed to provide a more precise measurement of tumor grade than previous techniques. Ipsogen, a leading French molecular diagnostic company, today launched the test, which resulted from the Powered by Affymetrix(TM) agreement signed in August 2007. Affymetrix is the only company to offer a continuous path to discover, develop and commercialize...http://www.cancercompass.com/cancer-news/1,14240,00.htm?rss=y Cancer Testing Offered To Jewish Women- May 27, 2008 TORONTO -- Canadian experts say they are offering a free test to Jewish women to determine if they have a strong chance of getting ovarian and breast cancers. Women's College Research Institute experts in Toronto said the test helps identify three mutated breast cancer genes frequently found in Ashkenazi Jewish people, the Toronto Globe and Mail reported Saturday. One of every 44 Ashkenazi Jewish people has the genetic mutation, said Steven Narod of the of Toronto's Women's College Research...http://www.cancercompass.com/cancer-news/1,14224,00.htm?rss=y First Patient Enrolled In Global Phase III Study Of Bevacizumab And Trastuzumab In Early Breast Cancer- May 27, 2008 PARIS -- Collaborative groups set out to confirm potential benefits of anticancer therapies to treat women with breast cancer A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin(R)) and the targeted...http://www.cancercompass.com/cancer-news/1,14222,00.htm?rss=y Node-Negative Early Stage Breast Cancer Patients Benefit From Taxotere-based Chemotherapy- May 27, 2008 BRIDGEWATER, N.J. -- Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced today that for women with high-risk node-negative early stage breast cancer adjuvant treatment (post surgery) with Taxotere(R) (docetaxel) Injection Concentrate as part of the TAC regimen (Taxotere(R), doxorubicin, cyclophosphamide) was associated with a significant improvement in Disease Free Survival (DFS) compared to a standard FAC regimen (5-Fluorouracil, doxorubicin,...http://www.cancercompass.com/cancer-news/1,14223,00.htm?rss=y Susan G. Komen For The Cure Encourages Nation To Go Passionately Pink- May 27, 2008 As part of its vision to realize a world without breast cancer, Susan G. Komen for the Cure(R) is encouraging people to show their true colors by participating in Passionately Pink for the Cure(R), a simple national fundraising program that inspires breast cancer advocacy and honors those affected by the disease. Registration for the 2008 program is now open at the newly redesigned http:www.passionatelypink.org.Passionately Pink for the Cure is a grassroots program in which companies,...http://www.cancercompass.com/cancer-news/1,14226,00.htm?rss=y Cancer Treatment Can Have Serious Side Effects- May 27, 2008 Chemotherapy helped cure Melinda Dutton's breast cancer, but it left her with a badly damaged heart. Bruce Ogden, who survived prostate cancer that had spread to his bones, lives with feminizing changes to his body from drugs he took to block testosterone that would have accelerated the malignancy. And Sally Coplin is almost totally deaf and can't produce saliva. Radiation treatment caused that, even as it rid her nasal passages of spiderweb-like tumors. Stories like these are what keep stem...http://www.cancercompass.com/cancer-news/1,14227,00.htm?rss=y |